GlassScriptPhysician profile
David W Monahan
NPI 1598712929
$975.66
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $154 · 2021: $636.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.30 | 2019-2021 | |
| Gilead Sciences, INC. | $119.24 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.28 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.20 | 2021 | |
| Janssen Biotech, INC. | $37.00 | 2021 | |
| Celgene Corporation | $32.57 | 2021 | |
| Ironwood Pharmaceuticals, INC | $27.55 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $21.76 | 2021 | |
| Intercept Pharmaceuticals, INC. | $19.17 | 2019 | |
| Concordia Pharmaceuticals INC. | $13.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Monahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.